Royal Bank of Canada’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-732
| Closed | -$2K | – | 7201 |
|
|
2017
Q4 | $2K | Sell |
732
-3,355
| -82% | -$13.7K | ﹤0.01% | 6338 |
|
|
2017
Q3 | $17K | Buy |
4,087
+2,983
| +270% | +$11.4K | ﹤0.01% | 6049 |
|
|
2017
Q2 | $3K | Buy |
1,104
+94
| +9% | +$373 | ﹤0.01% | 6229 |
|
|
2017
Q1 | $4K | Buy |
1,010
+4
| +0.4% | +$17 | ﹤0.01% | 6317 |
|
|
2016
Q4 | $4K | Hold |
1,006
| – | – | ﹤0.01% | 6384 |
|
|
2016
Q3 | $10K | Hold |
1,006
| – | – | ﹤0.01% | 5799 |
|
|
2016
Q2 | $6K | Hold |
1,006
| – | – | ﹤0.01% | 5923 |
|
|
2016
Q1 | $8K | Buy |
1,006
+653
| +185% | +$5.03K | ﹤0.01% | 5822 |
|
|
2015
Q4 | $5K | Sell |
353
-1,005
| -74% | -$17.3K | ﹤0.01% | 6190 |
|
|
2015
Q3 | $22K | Sell |
1,358
-174
| -11% | -$3.57K | ﹤0.01% | 5539 |
|
|
2015
Q2 | $34K | Buy |
1,532
+1,157
| +309% | +$18.3K | ﹤0.01% | 5432 |
|
|
2015
Q1 | $4K | Hold |
375
| – | – | ﹤0.01% | 5820 |
|
|
2014
Q4 | $4K | Buy |
375
+28
| +8% | +$304 | ﹤0.01% | 5876 |
|
|
2014
Q3 | $4K | Hold |
347
| – | – | ﹤0.01% | 5707 |
|
|
2014
Q2 | $6K | Buy |
347
+339
| +4,238% | +$5.98K | ﹤0.01% | 5541 |
|
|
2014
Q1 | $0 | Sell |
8
-56
| -88% | -$920 | ﹤0.01% | 6278 |
|
|
2013
Q4 | $1K | Buy |
64
+53
| +482% | +$592 | ﹤0.01% | 5856 |
|
|
2013
Q3 | $0 | Hold |
11
| – | – | ﹤0.01% | 6375 |
|
|
2013
Q2 | $0 | Buy |
+11
| New | +$141 | ﹤0.01% | 5883 |
|
Royal Bank of Canada's CASC Position: Q1 2018 in Review
Royal Bank of Canada sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 732 shares — an estimated $2K sold.
Royal Bank of Canada first reported a position in CASC in Q2 2013 and held it in 19 quarters. The position peaked at $34K in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Royal Bank of Canada reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Royal Bank of Canada sold 732 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $2K.
- Royal Bank of Canada first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
- Royal Bank of Canada's Cascadian Therapeutics, Inc. position peaked at $34K in Q2 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Royal Bank of Canada's 13F filing for Q1 2018, filed 15 May 2018.